Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus

OBJECTIVES: To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). METHODS: The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, N., Li, M., Zhang, M., Xu, J., Jiang, L., Gong, L., Wu, F., Gu, J., Zhao, J., Xiang, Y., Wang, Z., Zhao, Y., Zeng, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867648/
https://www.ncbi.nlm.nih.gov/pubmed/31747435
http://dx.doi.org/10.1371/journal.pone.0225516
_version_ 1783472113377607680
author Jiang, N.
Li, M.
Zhang, M.
Xu, J.
Jiang, L.
Gong, L.
Wu, F.
Gu, J.
Zhao, J.
Xiang, Y.
Wang, Z.
Zhao, Y.
Zeng, X.
author_facet Jiang, N.
Li, M.
Zhang, M.
Xu, J.
Jiang, L.
Gong, L.
Wu, F.
Gu, J.
Zhao, J.
Xiang, Y.
Wang, Z.
Zhao, Y.
Zeng, X.
author_sort Jiang, N.
collection PubMed
description OBJECTIVES: To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). METHODS: The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm(3) at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm(3). The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated. RESULTS: Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%). CONCLUSIONS: Thrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia.
format Online
Article
Text
id pubmed-6867648
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-68676482019-12-07 Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus Jiang, N. Li, M. Zhang, M. Xu, J. Jiang, L. Gong, L. Wu, F. Gu, J. Zhao, J. Xiang, Y. Wang, Z. Zhao, Y. Zeng, X. PLoS One Research Article OBJECTIVES: To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). METHODS: The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm(3) at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm(3). The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated. RESULTS: Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%). CONCLUSIONS: Thrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia. Public Library of Science 2019-11-20 /pmc/articles/PMC6867648/ /pubmed/31747435 http://dx.doi.org/10.1371/journal.pone.0225516 Text en © 2019 Jiang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Jiang, N.
Li, M.
Zhang, M.
Xu, J.
Jiang, L.
Gong, L.
Wu, F.
Gu, J.
Zhao, J.
Xiang, Y.
Wang, Z.
Zhao, Y.
Zeng, X.
Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
title Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
title_full Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
title_fullStr Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
title_full_unstemmed Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
title_short Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
title_sort chinese sle treatment and research group (cstar) registry: clinical significance of thrombocytopenia in chinese patients with systemic lupus erythematosus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867648/
https://www.ncbi.nlm.nih.gov/pubmed/31747435
http://dx.doi.org/10.1371/journal.pone.0225516
work_keys_str_mv AT jiangn chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT lim chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT zhangm chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT xuj chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT jiangl chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT gongl chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT wuf chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT guj chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT zhaoj chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT xiangy chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT wangz chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT zhaoy chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT zengx chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus
AT chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus